See more : PT Morenzo Abadi Perkasa Tbk (ENZO.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Orthofix Medical Inc. (OFIX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Orthofix Medical Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Bâloise Holding AG (0QQ3.L) Income Statement Analysis – Financial Results
- Aurinia Pharmaceuticals Inc. (AUPH) Income Statement Analysis – Financial Results
- Newell Brands Inc. (0K7J.L) Income Statement Analysis – Financial Results
- Ally Financial Inc. (0HD0.L) Income Statement Analysis – Financial Results
- Digia Oyj (DIGIA.HE) Income Statement Analysis – Financial Results
Orthofix Medical Inc. (OFIX)
About Orthofix Medical Inc.
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 746.64M | 460.71M | 464.48M | 406.56M | 459.96M | 453.04M | 433.82M | 409.79M | 396.49M | 402.28M | 400.53M | 462.32M | 578.99M | 564.37M | 545.64M | 519.68M | 490.32M | 365.36M | 313.30M | 286.64M | 203.71M | 177.60M | 162.36M | 131.78M | 121.28M | 104.10M | 90.00M | 77.20M | 52.30M | 39.60M | 31.40M | 28.00M | 20.90M |
| Cost of Revenue | 260.37M | 123.54M | 114.91M | 101.89M | 100.61M | 96.63M | 93.04M | 87.85M | 86.53M | 98.91M | 102.30M | 86.49M | 139.19M | 131.72M | 138.45M | 152.01M | 129.03M | 93.63M | 83.79M | 79.18M | 51.09M | 44.82M | 42.95M | 28.41M | 30.19M | 26.50M | 22.70M | 21.10M | 18.00M | 12.70M | 8.90M | 8.00M | 0.00 |
| Gross Profit | 486.27M | 337.17M | 349.57M | 304.67M | 359.35M | 356.41M | 340.79M | 321.94M | 309.96M | 303.37M | 298.23M | 375.83M | 439.80M | 432.65M | 407.19M | 367.66M | 361.29M | 271.73M | 229.52M | 207.46M | 152.62M | 132.78M | 119.41M | 103.37M | 91.10M | 77.60M | 67.30M | 56.10M | 34.30M | 26.90M | 22.50M | 20.00M | 20.90M |
| Gross Profit Ratio | 65.13% | 73.18% | 75.26% | 74.94% | 78.13% | 78.67% | 78.55% | 78.56% | 78.18% | 75.41% | 74.46% | 81.29% | 75.96% | 76.66% | 74.63% | 70.75% | 73.68% | 74.37% | 73.26% | 72.38% | 74.92% | 74.76% | 73.55% | 78.44% | 75.11% | 74.54% | 74.78% | 72.67% | 65.58% | 67.93% | 71.66% | 71.43% | 100.00% |
| Research & Development | 80.23M | 49.07M | 49.62M | 39.06M | 34.64M | 33.22M | 29.70M | 28.80M | 26.39M | 24.99M | 26.77M | 28.58M | 25.15M | 30.35M | 31.46M | 30.84M | 24.22M | 54.99M | 11.32M | 11.47M | 8.13M | 7.51M | 6.99M | 6.89M | 6.40M | 5.90M | 4.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 144.66M | 79.97M | 69.35M | 67.95M | 85.61M | 84.51M | 74.39M | 74.40M | 87.16M | 76.79M | 65.15M | 53.83M | 86.47M | 88.63M | 88.87M | 288.72M | 259.89M | 199.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 385.74M | 228.81M | 221.32M | 204.43M | 223.68M | 205.53M | 198.37M | 181.29M | 178.08M | 166.55M | 176.58M | 200.34M | 233.61M | 230.94M | 215.94M | 40.00K | 38.00K | 40.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 530.40M | 308.78M | 290.67M | 272.38M | 309.28M | 290.03M | 272.76M | 255.69M | 265.24M | 243.34M | 241.73M | 254.17M | 320.08M | 319.57M | 304.81M | 288.72M | 259.89M | 199.02M | 151.92M | 133.07M | 97.22M | 81.63M | 77.78M | 62.35M | 54.65M | 49.90M | 44.90M | 43.30M | 24.60M | 14.20M | 11.20M | 10.90M | 0.00 |
| Other Expenses | 14.76M | -3.15M | -3.34M | 8.38M | -8.14M | -6.38M | -4.00M | -17.18M | -259.00K | -2.90M | 490.00K | -3.68M | 5.60M | -6.26M | 7.04M | 305.05M | 18.16M | 8.87M | 6.57M | 7.92M | 6.68M | 703.00K | 4.14M | 4.03M | 6.83M | 6.50M | 6.50M | 6.20M | 2.20M | 1.10M | 700.00K | 800.00K | 0.00 |
| Operating Expenses | 625.38M | 357.84M | 340.29M | 311.44M | 343.92M | 323.25M | 302.46M | 284.49M | 291.63M | 270.62M | 271.18M | 284.85M | 350.82M | 343.66M | 343.31M | 624.61M | 302.26M | 262.88M | 169.81M | 152.46M | 112.03M | 89.84M | 88.91M | 73.27M | 67.88M | 62.30M | 56.20M | 49.50M | 26.80M | 15.30M | 11.90M | 11.70M | 0.00 |
| Cost & Expenses | 885.75M | 481.39M | 455.21M | 413.33M | 444.53M | 419.88M | 395.50M | 372.35M | 378.15M | 369.53M | 373.48M | 371.34M | 490.01M | 475.38M | 481.76M | 776.62M | 431.29M | 356.51M | 253.60M | 231.64M | 163.12M | 134.66M | 131.86M | 101.68M | 98.07M | 88.80M | 78.90M | 70.60M | 44.80M | 28.00M | 20.80M | 19.70M | 0.00 |
| Interest Income | 0.00 | 1.29M | 1.84M | 2.48M | 122.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 326.00K | 330.00K | 193.00K | 542.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.63M | 1.29M | 1.84M | 2.48M | 122.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.83M | 0.00 | 9.46M | 17.23M | 24.63M | 20.22M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 60.60M | 29.02M | 29.60M | 30.55M | 24.70M | 18.66M | 20.12M | 20.84M | 20.92M | 2.28M | 22.66M | 20.26M | 22.78M | 22.52M | 22.34M | 32.68M | 32.33M | 16.96M | 17.53M | 15.08M | 6.95M | 5.83M | 7.95M | 7.38M | 6.83M | 6.50M | 6.50M | 6.20M | 2.20M | 1.10M | 700.00K | 800.00K | 0.00 |
| EBITDA | -79.45M | 12.60M | 17.94M | 32.66M | -2.23M | 41.54M | 60.94M | 39.87M | 29.92M | 40.64M | 14.05M | 96.19M | 53.27M | 112.15M | 87.19M | -243.53M | 70.39M | 25.81M | 116.76M | 70.08M | 47.53M | 48.77M | 38.45M | 41.51M | 30.05M | 21.77M | 17.56M | 12.80M | 9.70M | 12.70M | 11.30M | 9.10M | 20.90M |
| EBITDA Ratio | -10.64% | -5.17% | 5.78% | 8.83% | 10.79% | 8.00% | 8.26% | 9.63% | 6.92% | 12.59% | 20.43% | 24.06% | 19.30% | 19.70% | 15.60% | 15.80% | 22.83% | 6.07% | 11.48% | 24.53% | 26.67% | 28.93% | 23.91% | 2.39% | 24.76% | 16.52% | 20.67% | 18.78% | 62.72% | 29.29% | 35.03% | 31.43% | 100.00% |
| Operating Income | -139.11M | -20.67M | -6.23M | 1.62M | 24.94M | 30.09M | 40.81M | 21.07M | 9.26M | 17.14M | -5.09M | 89.01M | 32.52M | 88.99M | 63.88M | -256.95M | 38.06M | 8.85M | 59.71M | 55.00M | 40.58M | 42.94M | 30.50M | 22.73M | 23.22M | 15.30M | 11.10M | 6.60M | 7.50M | 11.60M | 10.60M | 8.30M | 20.90M |
| Operating Income Ratio | -18.63% | -4.49% | -1.34% | 0.40% | 5.42% | 6.64% | 9.41% | 5.14% | 2.33% | 4.26% | -1.27% | 19.25% | 5.62% | 15.77% | 11.71% | -49.44% | 7.76% | 2.42% | 19.06% | 19.19% | 19.92% | 24.18% | 18.78% | 17.24% | 19.14% | 14.70% | 12.33% | 8.55% | 14.34% | 29.29% | 33.76% | 29.64% | 100.00% |
| Total Other Income/Expenses | -9.57M | -4.44M | -5.18M | -366.50K | -8.27M | -7.21M | -4.42M | -2.04M | -748.00K | -4.68M | 589.00K | -7.10M | -33.88M | -10.96M | -23.85M | -38.09M | -23.32M | -2.53M | 35.81M | -4.64M | -1.27M | -2.41M | -1.67M | 38.33M | -2.39M | 1.70M | -3.86M | -4.30M | -24.70M | 300.00K | -300.00K | -800.00K | -20.90M |
| Income Before Tax | -148.68M | -17.71M | -13.50M | -368.00K | -27.05M | 22.89M | 36.39M | 19.02M | 8.51M | 12.46M | -6.52M | 82.73M | 20.70M | 72.40M | 40.02M | -295.04M | 14.80M | 6.32M | 95.52M | 50.36M | 39.32M | 40.53M | 28.83M | 61.05M | 20.83M | 17.00M | 7.20M | 2.30M | -17.20M | 11.90M | 10.30M | 7.50M | 0.00 |
| Income Before Tax Ratio | -19.91% | -3.84% | -2.91% | -0.09% | -5.88% | 5.05% | 8.39% | 4.64% | 2.15% | 3.10% | -1.63% | 17.89% | 3.58% | 12.83% | 7.33% | -56.77% | 3.02% | 1.73% | 30.49% | 17.57% | 19.30% | 22.82% | 17.76% | 46.33% | 17.17% | 16.33% | 8.00% | 2.98% | -32.89% | 30.05% | 32.80% | 26.79% | 0.00% |
| Income Tax Expense | 2.72M | 2.04M | 24.88M | -2.89M | 1.41M | 9.07M | 29.10M | 15.53M | 10.85M | 16.20M | 9.16M | 28.79M | 21.78M | 28.19M | 15.55M | -66.48M | 3.77M | 13.36M | 22.11M | 16.21M | 14.59M | 12.88M | 7.87M | 16.23M | 7.91M | 2.70M | 4.10M | 2.80M | 2.60M | 2.80M | 2.60M | 1.30M | -5.00M |
| Net Income | -151.40M | -19.75M | -38.38M | 2.52M | -28.46M | 13.81M | 6.22M | 3.06M | -2.81M | -8.54M | -28.48M | 51.30M | -1.07M | 44.21M | 24.47M | -228.55M | 10.97M | -7.04M | 73.40M | 34.15M | 24.73M | 25.91M | 20.96M | 44.82M | 12.91M | 14.30M | 3.10M | -500.00K | -19.80M | 9.10M | 7.70M | 6.20M | 5.00M |
| Net Income Ratio | -20.28% | -4.29% | -8.26% | 0.62% | -6.19% | 3.05% | 1.43% | 0.75% | -0.71% | -2.12% | -7.11% | 11.10% | -0.19% | 7.83% | 4.49% | -43.98% | 2.24% | -1.93% | 23.43% | 11.91% | 12.14% | 14.59% | 12.91% | 34.01% | 10.65% | 13.74% | 3.44% | -0.65% | -37.86% | 22.98% | 24.52% | 22.14% | 23.92% |
| EPS | -4.12 | -0.98 | -1.95 | 0.13 | -1.51 | 0.75 | 0.34 | 0.17 | -0.15 | -0.46 | -1.52 | 2.70 | -0.06 | 2.51 | 1.43 | -13.37 | 0.66 | -0.44 | 4.61 | 2.22 | 1.76 | 1.96 | 1.60 | 3.40 | 0.99 | 1.10 | 0.24 | -0.04 | -1.78 | 0.84 | 0.71 | 0.61 | 0.57 |
| EPS Diluted | -4.12 | -0.98 | -1.95 | 0.13 | -1.51 | 0.73 | 0.34 | 0.17 | -0.15 | -0.46 | -1.52 | 2.64 | -0.06 | 2.47 | 1.42 | -13.37 | 0.64 | -0.44 | 4.51 | 2.14 | 1.68 | 1.76 | 1.42 | 3.20 | 0.97 | 1.07 | 0.23 | -0.04 | -1.78 | 0.84 | 0.71 | 0.61 | 0.57 |
| Weighted Avg Shares Out | 36.73M | 20.05M | 19.69M | 19.27M | 18.90M | 18.49M | 18.12M | 18.14M | 18.80M | 18.46M | 18.70M | 18.98M | 18.22M | 17.60M | 17.12M | 17.10M | 16.64M | 16.17M | 15.91M | 15.40M | 14.06M | 13.20M | 13.09M | 13.18M | 13.03M | 12.97M | 12.92M | 12.50M | 11.12M | 10.83M | 10.85M | 10.16M | 8.77M |
| Weighted Avg Shares Out (Dil) | 36.73M | 20.05M | 19.69M | 19.39M | 18.90M | 18.91M | 18.50M | 18.46M | 18.80M | 18.46M | 18.70M | 19.39M | 18.22M | 17.91M | 17.20M | 17.10M | 17.05M | 16.17M | 16.29M | 15.97M | 14.68M | 14.69M | 14.74M | 13.99M | 13.36M | 13.29M | 13.48M | 12.50M | 11.12M | 10.83M | 10.85M | 10.16M | 8.77M |
Shareholders of Orthofix Medical Inc. Should Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your Rights - OFIX
NEW YORK, NY / ACCESSWIRE / October 20, 2024 / If you suffered a loss on your Orthofix Medical Inc. (NASDAQ:OFIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 21, 2024 in Orthofix Medical Inc. Lawsuit - OFIX
NEW YORK, NY / ACCESSWIRE / October 20, 2024 / If you suffered a loss on your Orthofix Medical Inc. (NASDAQ:OFIX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for...
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Orthofix Medical Inc.
LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of 10(b)...
OFIX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Orthofix Medical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / October 20, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX)...
FINAL REMINDER OFIX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Orthofix Medical Inc. Investors to Participate in the Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / October 20, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX)...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Orthofix Medical Inc. - OFIX
NEW YORK, NY / ACCESSWIRE / October 19, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Orthofix Medical Inc. ("Orthofix" or the "Company") (NASDAQ:OFIX). Such investors are advised to contact Danielle Peyton at [email protected]...
Orthofix Medical Inc Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Help The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of 10(b)...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Orthofix
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Orthofix To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Orthofix between October 11, 2022, and September...
RLF, SKILLED INVESTOR COUNSEL, Encourages Orthofix Medical Inc. Investors to Secure Counsel Before Important October 21 Deadline in Securities Class Action – OFIX
NEW YORK, Oct. 18, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Orthofix Medical Inc. (NASDAQ: OFIX) between October 11, 2022 and September 12, 2023, both dates inclusive (the...
OFIX Investors Have Opportunity to Lead Orthofix Medical Inc. Securities Fraud Lawsuit
LOS ANGELES , Oct. 18, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Orthofix Medical Inc. ("Orthofix" or the "Company") (NASDAQ: OFIX)....
Source: https://incomestatements.info
Category: Stock Reports